Entries by Maren Kühr

Data-driven excellence: the cornerstone of clinical research

Essential areas such as study planning, interpretation, regulatory guidance, and key study design decisions remain human responsibilities, although AI increasingly supports routine tasks. X-act gets involved after the preclinical phase supporting clients in all clinical research phases from Phase I to IV and beyond. Their service ranges from initial planning to final analysis, reporting, and regulatory submission. European Biotechnology spoke with Jasmin Atarodi, Managing Director of X-act Cologne Clinical Research GmbH, about the benefits of partnering with experienced data specialists.

Celonic’s Strategic Alliance in ADCs

The Celonic Group and CARBOGEN AMCIS AG have formed a strategic alliance to offer a fully integrated Antibody Drug Conjugate (ADC) development and manufacturing platform. This partnership combines Celonic’s biologics expertise with CARBOGEN AMCIS’s payload synthesis and conjugation capabilities, creating a seamless, end-to-end solution for ADC developers.

Vienna: The centre of the European biotech world

This year, BIO-Europe, Europe’s leading partnering event for the entire biotech ecosystem, will take place in Vienna. From 3 to 5 November, the industry’s most important decision-makers will meet here to negotiate partnerships, contracts and financing, and to learn about the latest developments and trends. With over 5,700 participants from 60 countries, 2025 is set to see a record number of delegates, sponsors, exhibitors and presenting companies.

Ultra-low freezer for intensive use

Safeguarding temperature-sensitive materials is critical, and Ultra-Low Freezers (ULTs) ensure sample integrity at very low temperatures. Today’s customers demand not just reliability, but also sustainability under intensive use. The new U701V from B Medical Systems, with variable-speed technology, delivers the perfect balance: uncompromised performance, reliability, and sustainability.

US-policy-made challenges for the bio-pharma sector

New developments under the current U.S. administration may be a challenge for the pharma/biotech industry: the Inflation Reduction Act, Orange Book Challenges, Most Favored Nation Policy, and the new Trump-Lutnick Patent Tax. And it will likely affect European pharma and biotech.

European biotech back on stage

After two challenging years marked by rising interest rates and frozen capital markets, European biotech is back in the spotlight. The catalyst? Late-stage clinical success.

Meeting global market challenges

The global biologics industry is entering a new phase of maturity. As costs tighten and timelines accelerate, CDMOs must deliver uncompromised quality while driving efficiency. Rezon Bio, an EU-based biologics CDMO with state-of-the-art facilities and a client-centric approach, was established to meet biotech and pharmaceutical client needs with agility, pragmatism, and trust.

New CEO strengthens management

FairJourney Biologics (Porto, PT) has appointed Dr Werner Lanthaler, long-standing Evotec CEO, as Chief Executive Officer. Founder António Parada will focus on innovation strategy on the Supervisory Board.

New CEO takes over

Contract Research Organization Julius Clinical (NL) appointed Bassem Saleh as its new Chief Executive Officer. His predecessor, Martijn Wallert, will become an advisor to the Executive Board.

New Chief Scientific Officer has started

Tessellate Bio (Naarden, Netherlands; Stevenage, UK) appointed Dr Katie Chapman as Chief Scientific Officer (CSO) at the end of September. She succeeds Dr Jürgen Moll, who will be available to the company in an advisory capacity.